ArticleCancer research2018
Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 66 papers.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
3.5field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 86 citations in OpenAlex.
- Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- SNU523 Inhibits Pancreatic Cancer through the Dual Suppression of STAT3 and MEK Signaling Pathways.ACS omega · 2026Article
- Amphiregulin drives EGFR-dependent genome stability in colorectal cancer and represents a targetable vulnerability.Oncogene · 2026Article
- Repurposing T-type calcium channel blocker lomerizine as a therapeutic strategy for glioblastoma.JCI insight · 2026Article
- ERK1/2 hijack STAT3 via Thr714 phosphorylation to suppress gene expression.Cell communication and signaling : CCS · 2026Article
- Advancements on the synergistic application of oncolytic viruses and molecularly targeted therapies for the treatment of solid tumors (Review).International journal of oncology · 2026Review
- KRAS-driven cytokine-metabolic crosstalk shapes immune exclusion in pancreatic ductal adenocarcinoma.Frontiers in genetics · 2026Review
- STAT3 at the tumor-immune interface: mechanisms of immune escape and therapeutic opportunities.Frontiers in immunology · 2026Review
- Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer.Cancer biology & medicine · 2025Review
- Interpretable prediction of drug synergy for breast cancer by random forest with features from Boolean modeling of signaling pathways.Scientific reports · 2025Article
- STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASCancer science · 2025Article
- Evaluating the specific STAT3 inhibitor YHO-1701 in ovarian cancer cell lines and patient-derived cell models: efficacy, mechanisms, and therapeutic potential.Journal of gynecologic oncology · 2025Article
- Targeting KRAS-mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2.Molecular oncology · 2025Article
- New insights into Notch signaling as a crucial pathway of pancreatic cancer stem cell behavior by chrysin-polylactic acid-based nanocomposite.Discover oncology · 2025Review
- Sex-Related Differences in Pancreatic Ductal Adenocarcinoma Progression and Response to Therapy.International journal of molecular sciences · 2024Review
- Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer.Cancer discovery · 2024Article
- Unveiling the resistance to therapies in pancreatic ductal adenocarcinoma.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2024Review
- The HOXC10/NOD1/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer.Bone research · 2024Article
- CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.Scientific reports · 2024Article
- PKCι induces differential phosphorylation of STAT3 to modify STAT3-related signaling pathways in pancreatic cancer cells.Journal of cell communication and signaling · 2023Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 2 institutions in 1 country.
Nagaraj S NagathihalliDepartment of Surgery, University of Miami Miller School of Medicine, Miami, Florida.
Jason A CastellanosDepartment of Surgery, Vanderbilt University School of Medicine, Nashville, Tennessee.
Purushottam LamichhaneDepartment of Surgery, University of Miami Miller School of Medicine, Miami, Florida.
Fanuel MessaggioDepartment of Surgery, University of Miami Miller School of Medicine, Miami, Florida.
Chanjuan ShiDepartment of Pathology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Xizi DaiDepartment of Surgery, University of Miami Miller School of Medicine, Miami, Florida.
Priyamvada RaiSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Xi ChenSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.
Michael N VanSaunDepartment of Surgery, University of Miami Miller School of Medicine, Miami, Florida.
Nipun B MerchantDepartment of Surgery, University of Miami Miller School of Medicine, Miami, Florida. nmerchant@med.miami.edu.
University of Miami · USVanderbilt University · US
Funding
Stat3 Signaling in Pancreas CancerR01CA161976 · NCI · VANDERBILT UNIVERSITY · PI MERCHANT, NIPUN B. · 2012 to 2022
$3.4MResearch Training Program in Surgical OncologyT32CA211034 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MERCHANT, NIPUN B. · 2016 to 2025
$2.7MMutT Homolog 1 as a Novel Mediator of RAS Oncogene-Induced Pro-Malignant PathwaysR01CA175086 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI RAI, PRIYAMVADA · 2013 to 2017
$1.6MTargeting cytokine mediated CREB activation in pancreatic cancerR21CA209536 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI NAGATHIHALLI, NAGARAJ S. · 2016 to 2017
$367kNCI NIH HHS R01 CA161976NCI NIH HHS R01 CA175086NCI NIH HHS R21 CA209536NCI NIH HHS T32 CA211034
Abstract
Major contributors to therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC) include
Indexed as
AmphiregulinAnimalsCarcinoma, Pancreatic DuctalCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansLigandsMAP Kinase Kinase 1MiceMice, NudeMutationNeoplasm TransplantationPancreatic NeoplasmsPhosphorylationProto-Oncogene Proteins p21(ras)AmphiregulinAREG protein, humanKRAS protein, humanLigandsMAP Kinase Kinase 1Proto-Oncogene Proteins p21(ras)ras ProteinsSTAT3 protein, humanSTAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.